Meinolf J. Suttorp

Dresden, SN, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 128 publications

Erratum: [Corrigendum] Imatinib mesylate and nilotinib decrease synthesis of bone matrix in vitro.

Erratum: [Corrigendum] Imatinib mesylate and nilotinib decrease synthesis of bone matrix in vitro.

Journal: Oncology letters
Published: June 22, 2026

Reframing chronic myeloid leukemia outcomes beyond survival: a perspective of quality of life and patient-centered data.

Reframing chronic myeloid leukemia outcomes beyond survival: a perspective of quality of life and patient-centered data.

Journal: Blood reviews
Published: May 19, 2026

Characteristics and Outcomes of Adolescents (15-18 Years) with Chronic Myelogenous Leukemia (CML) in Chronic Phase: The Experience of the International Registry of Childhood CML.

Characteristics and Outcomes of Adolescents (15-18 Years) with Chronic Myelogenous Leukemia (CML) in Chronic Phase: The Experience of the International Registry of Childhood CML.

Journal: Cancers
Published: April 08, 2026

Therapeutic Drug Monitoring of Imatinib in Paediatric Chronic Myeloid Leukaemia: Towards Practical Implementation and Interpretation of Measured Plasma Concentrations.

Therapeutic Drug Monitoring of Imatinib in Paediatric Chronic Myeloid Leukaemia: Towards Practical Implementation and Interpretation of Measured Plasma Concentrations.

Journal: Clinical pharmacokinetics
Published: December 18, 2025

Dynamics of BCR::ABL1 transcript levels and clinical outcomes after switch to second-line therapy in pediatric chronic myeloid leukemia.

Dynamics of BCR::ABL1 transcript levels and clinical outcomes after switch to second-line therapy in pediatric chronic myeloid leukemia.

Journal: HemaSphere
Published: October 08, 2025

Children with chronic-phase chronic myeloid leukemia: characteristics and outcomes from the International Registry of Childhood CML.

Children with chronic-phase chronic myeloid leukemia: characteristics and outcomes from the International Registry of Childhood CML.

Journal: Haematologica
Published: May 22, 2025

Complications at Diagnosis of Pediatric Chronic Myeloid Leukemia in Chronic Phase.

Complications at Diagnosis of Pediatric Chronic Myeloid Leukemia in Chronic Phase.

Journal: Pediatric blood & cancer
Published: April 24, 2025

Catch-up growth after switch to asciminib in a twin with chronic myeloid leukaemia.

Catch-up growth after switch to asciminib in a twin with chronic myeloid leukaemia.

Journal: Lancet (London, England)
Published: April 11, 2025

Genomic variant profiling in blast-phase paediatric chronic myeloid leukaemia: Predisposing and driving alterations.

Genomic variant profiling in blast-phase paediatric chronic myeloid leukaemia: Predisposing and driving alterations.

Journal: British journal of haematology
Published: February 14, 2025

Cases of Patients Treated in Countries With Limited Resources and Discussed by Experts of the International CML Foundation (iCMLf)-Case No. 2: Treatment-Free Remission After 9 Years of Imatinib Treatment Without Prior Achievement of Sustained Deep Molecular Response.

Cases of Patients Treated in Countries With Limited Resources and Discussed by Experts of the International CML Foundation (iCMLf)-Case No. 2: Treatment-Free Remission After 9 Years of Imatinib Treatment Without Prior Achievement of Sustained Deep Molecular Response.

Journal: Case reports in oncological medicine
Published: January 09, 2025

How I treat chronic myeloid leukemia in children and adolescents.

How I treat chronic myeloid leukemia in children and adolescents.

Journal: Blood
Published: January 06, 2025

Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia: Data from a real-world setting.

Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia: Data from a real-world setting.

Journal: British journal of haematology
Published: November 20, 2024
Showing 1-12 of 128

Last Updated: 09/26/2026